Douglas Tsao

Brian Abrahams

Graig Suvannavejh

Myles Minter

Yatin Suneja

Ami Fadia

Paul Matteis

Chen Yang

Hanxing Gao

John Boyle

Julian Pino

Poorna Kannan

Tessa Romero

Tess Romero

- Nomura announced **class-leading weight loss data** for **NMRA-215**, its oral NLRP3 inhibitor for obesity, from diet-induced obesity studies, showing up to **19% body weight loss** as monotherapy and **26%** in combination with semaglutide.  **[0001885522_2205294_2]** **[0001885522_2205294_4]**  Phase I studies for NMRA-215 are expected to initiate in **2026**.  **[0001885522_2205294_2]** 
- **NMRA-898 has entered the clinic**, marking a major milestone for the M4 PAM franchise for schizophrenia, with a comprehensive franchise update anticipated by **mid-2026**.  **[0001885522_2205294_2]** **[0001885522_2205294_14]** 
- Top-line data from the Phase Ib signal-seeking study for **NMRA-511** in Alzheimer's disease agitation is expected around the **end of 2025**.  **[0001885522_2205294_2]** 
- Top-line data from the COLASTAL III and II studies for **Nevacoprant** are on track to be reported in the **first and second quarters of 2026**.  **[0001885522_2205294_2]**

Nomura Provides Updates on Pipeline Programs and Clinical Data Readouts

- Neumora Therapeutics announced **class-leading weight loss data** for its oral NLRP3 inhibitor, **NMRA-215**, in diet-induced obesity (DIO) studies, demonstrating up to **19%** body weight loss as monotherapy and **26%** in combination with semaglutide.  **[0001885522_2205482_1]** **[0001885522_2205482_2]** 
- Phase 1 studies for **NMRA-215** in obesity are expected to initiate in **Q1 2026**, with **12-week human proof-of-concept data** anticipated in **2026**.  **[0001885522_2205482_1]** **[0001885522_2205482_6]** 
- **NMRA-898**, an M4PAM candidate for schizophrenia, has entered into the clinic.  **[0001885522_2205482_1]** 
- The company expects top-line data from the Phase 1b study of **NMRA-511** in Alzheimer's disease agitation around the **end of 2025**, and from the **COASTAL-3 and -2 studies** with **navacaprant** in **Q1 and Q2 2026**, respectively.  **[0001885522_2205482_1]** 
- Neumora's cash runway extends into **2027**, supporting multiple value-creating catalysts over the next **12 months**.  **[0001885522_2205482_1]**

Neumora Therapeutics Announces Positive NMRA-215 Obesity Data and Upcoming Clinical Milestones

- Neumora announced **class-leading weight loss data** for its oral NLRP3 inhibitor, **NMRA-215**, from diet-induced obesity (DIO) studies, showing **up to 19% body weight loss** as monotherapy and **26% in combination with Semaglutide** in DIO models.  **[0001885522_2205566_1]** **[0001885522_2205566_2]**  Phase I studies for NMRA-215 are expected to initiate in **Q1 2026**.  **[0001885522_2205566_1]** 
- Top-line data from the **phase I-B signal-seeking study** for **NMRA-511** in Alzheimer's disease agitation is anticipated around the **end of 2025**.  **[0001885522_2205566_1]** 
- For **Navacaprant**, top-line data from the **KOASTAL-3 and KOASTAL-2 studies** in Major Depressive Disorder (MDD) are expected in **Q1 2026 and Q2 2026**, respectively.  **[0001885522_2205566_1]** 
- Neumora projects **up to six distinct value-creating catalysts** over the next 12 months, all supported by its cash runway guidance extending into **2027**.  **[0001885522_2205566_1]** **[0001885522_2205566_16]**

Neumora provides pipeline updates and announces new data for NMRA-215

- Neumora Therapeutics announced **class-leading weight loss data** from diet-induced obesity studies with **NMRA-215**, a highly brain-penetrant NLRP3 inhibitor, showing up to **19% body weight loss** as a monotherapy and **26%** in combination with semaglutide.  **[0001885522_2205276_1]** **[0001885522_2205276_2]** 
- The company also announced that **NMRA-898** has entered into the clinic, marking a milestone for its M4PAM candidates for schizophrenia.  **[0001885522_2205276_1]** 
- Key upcoming clinical milestones include top-line data for **NMRA-511** in Alzheimer's disease agitation around the **end of 2025**, and for **navacaprant** in Q1 and Q2 **2026**.  **[0001885522_2205276_1]** 
- Neumora expects to initiate Phase 1 studies for **NMRA-215** in obesity in **Q1 2026** and share updates from its M4PAM franchise by **mid-2026**.  **[0001885522_2205276_1]** 
- The company anticipates up to **six distinct catalysts** over the next 12 months, all within its cash runway guidance which extends into **2027**.  **[0001885522_2205276_1]** **[0001885522_2205276_16]**

Neumora Therapeutics Announces Positive Preclinical Data for Obesity Drug Candidate and Pipeline Updates

- Neumora Therapeutics, Inc. announced **positive preclinical data for NMRA-215**, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, on **October 27, 2025**.  **[1885522_0001193125-25-250656_nmra-20251027.htm:0]** **[1885522_0001193125-25-250656_nmra-ex99_1.htm:0]** 
- In diet-induced obesity (DIO) mouse studies, NMRA-215 demonstrated **class-leading weight loss of up to 19% as a monotherapy** and **26% in combination with high doses of semaglutide**.  **[1885522_0001193125-25-250656_nmra-20251027.htm:0]** **[1885522_0001193125-25-250656_nmra-ex99_1.htm:0]** 
- The company plans to **initiate a Phase 1 clinical study for NMRA-215 in the first quarter of 2026**.  **[1885522_0001193125-25-250656_nmra-ex99_1.htm:0]**

Neumora Therapeutics (NMRA)